loading
Schlusskurs vom Vortag:
$0.9293
Offen:
$0.93
24-Stunden-Volumen:
18.48M
Relative Volume:
1.44
Marktkapitalisierung:
$254.62M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.0261
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+9.45%
1M Leistung:
+18.97%
6M Leistung:
+6.14%
1J Leistung:
-52.82%
1-Tages-Spanne:
Value
$0.8209
$0.9498
1-Wochen-Bereich:
Value
$0.7225
$0.97
52-Wochen-Spanne:
Value
$0.2836
$2.45

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Firmenname
Lexicon Pharmaceuticals Inc
Name
Telefon
(281) 863-3000
Name
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Mitarbeiter
103
Name
Twitter
@LexPharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
0.8209 254.62M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-05 Herabstufung Leerink Partners Outperform → Market Perform
2024-06-17 Eingeleitet H.C. Wainwright Buy
2024-04-30 Eingeleitet Leerink Partners Outperform
2023-03-07 Eingeleitet Jefferies Hold
2022-08-12 Eingeleitet Piper Sandler Overweight
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2021-01-29 Herabstufung Wedbush Outperform → Neutral
2020-12-08 Hochstufung Citigroup Neutral → Buy
2020-11-18 Hochstufung Gabelli & Co Hold → Buy
2019-12-11 Herabstufung Gabelli & Co Buy → Hold
2019-11-08 Herabstufung Citigroup Buy → Neutral
2019-09-11 Hochstufung Gabelli & Co Hold → Buy
2019-07-29 Herabstufung Stifel Buy → Hold
2019-03-25 Hochstufung Gabelli & Co Sell → Hold
2018-07-31 Bestätigt Stifel Buy
2018-02-23 Herabstufung Needham Buy → Hold
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-03-01 Bestätigt H.C. Wainwright Buy
2017-03-01 Bestätigt Wedbush Outperform
2016-10-07 Eingeleitet H.C. Wainwright Buy
2016-08-05 Bestätigt Wedbush Outperform
2016-08-02 Eingeleitet Citigroup Buy
2016-03-02 Bestätigt Wedbush Outperform
2015-11-09 Bestätigt Wedbush Outperform
2015-09-28 Hochstufung Gabelli & Co Sell → Hold
2015-09-18 Herabstufung Gabelli & Co Hold → Sell
2015-08-10 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
Jun 18, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView

Jun 18, 2025
pulisher
Jun 13, 2025

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st

Jun 13, 2025
pulisher
Jun 11, 2025

Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener

Jun 11, 2025
pulisher
Jun 08, 2025

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Jun 08, 2025
pulisher
Jun 05, 2025

Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada

Jun 05, 2025
pulisher
May 30, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World

May 30, 2025
pulisher
May 29, 2025

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 21, 2025

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN

May 21, 2025
pulisher
May 20, 2025

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

May 20, 2025
pulisher
May 19, 2025

Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

May 19, 2025
pulisher
May 17, 2025

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

May 17, 2025
pulisher
May 17, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

May 17, 2025
pulisher
May 15, 2025

Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN

May 15, 2025
pulisher
May 15, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals (LXRX) Reports Higher Q1 Revenue and Key Strategic Developments | LXRX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals (LXRX) Pre-Earnings Options Activity Rev - GuruFocus

May 14, 2025
pulisher
May 14, 2025

LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Barclays PLC - Defense World

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlig - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lexicon: Q1 Earnings Snapshot - New Haven Register

May 14, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals (LXRX) Secures Major Licensing Deal with Novo Nordisk - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Lexicon Q1 2025 beats EPS expectations, stock declines - Investing.com

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings: EPS Beats E - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Q1 Operating Income USD -25.679 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial - Stock Titan

May 13, 2025
pulisher
May 12, 2025

A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq

May 12, 2025
pulisher
May 07, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference | LXRX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals Announces Exclusive Fireside Chat at HC Wainwright BioConnect Conference - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

May 06, 2025
pulisher
Apr 30, 2025

Carcinoid Syndrome Diarrhea Treatment Market To Reach US$ - openPR.com

Apr 30, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Lexicon Pharmaceuticals, Inc. (LXRX)Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019 - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Top 2 Health Care Stocks That May Crash This Month - Benzinga

Apr 25, 2025
pulisher
Apr 22, 2025

Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider

Apr 22, 2025
pulisher
Apr 09, 2025

Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada

Apr 09, 2025

Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Sullivan Diane E.
Director
May 13 '25
Option Exercise
0.00
36,810
0
36,810
SOBECKI CHRISTOPHER J
Director
May 13 '25
Option Exercise
0.00
36,810
0
203,865
BARKER SAM L
Director
May 13 '25
Option Exercise
0.00
36,810
0
124,459
Amouyal Philippe
Director
May 13 '25
Option Exercise
0.00
36,810
0
285,174
DEBBANE RAYMOND
Director
May 13 '25
Option Exercise
0.00
36,810
0
1,385,689
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):